Protein expression is an integral tool in biological research and it is gaining significant traction as a pharmaceutical production mechanism for biological therapeutics. The biotechnology industry uses both cell types prokaryotic (bacteria) and eukaryotic (animal, fungi, and plant) to synthesize recombinant proteins. The choice of the host cell depends on the protein expressed. The demand for recombinant proteins has increased as more applications in several fields are commercially available. Recombinant proteins have been utilized as tools for cellular and molecular biology.
Market Dynamics
The demand for protein therapeutics has increased considerably, owing to increase in prevalence of chronic diseases and development of plasma-derived therapies. In recent years, proteins expression systems have gained significant traction for therapeutic applications and the number of proteins launched or approved into clinical trials has continually increased. According to the National Center for Biotechnology Information (NCBI) data of 2017, the U.S. Food and Drug Administration (FDA) approved more than 140 recombinant therapeutic proteins for human use and several hundred are currently in development.
However, high cost associated with therapeutic proteins and stringent government regulations towards approval of protein therapies are expected to hinder market growth. For instance, in India, a vial of Avastin (Bevacizumab mostly produced by the mammalian cell expression system), a monoclonal antibody, cost between USD 372.65 to USD 402.46. Moreover, immunogenicity is also a major concern for all recombinant drugs, as all biotechnologically produced therapeutics may exhibit some form of immunogenicity.
Key features of the study
- This report provides in-depth analysis of the protein expression systems market, market size (USD Bn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2026 – 2033, considering 2025, as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
- It profiles key players in the global protein expression systems market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key players covered as a part of this study include Agilent Technologies, Inc., Becton, Dickinson & Company, Lonza Group Ltd., GenScript Biotech Corporation, Bio-Rad Laboratories, Inc., Merck KGaA, QIAGEN N.V., Thermo Fisher Scientific Inc., Takara Bio Inc., Synthetic Genomics Inc., Lucigen Corporation, Promega Corporation, ARTES Biotechnology GmbH, ProteoGenix, Addgene Inc., Geneva Biotech, Profacgen, and Peak Proteins Ltd.
- Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
- The global protein expression systems market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for protein expression systems market, research and consulting firms, new entrants, and financial analysts
Market Segmentation
- By Expression System Insights (Revenue, USD Bn, 2021 - 2033)
- Mammalian Expression Systems
- Insect Expression Systems
- Bacterial Expression Systems
- Plant Expression Systems
- Yeast Expression Systems
- Cell Free Expression Systems
- By Product Type Insights (Revenue, USD Bn, 2021 - 2033)
- Competent Cells
- Instruments
- Reagents
- Others
- By Application Insights (Revenue, USD Bn, 2021 - 2033)
- Protein Therapeutics
- Research Studies
- By Region Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players
- Agilent Technologies, Inc.
- Becton, Dickinson & Company
- Lonza Group Ltd.
- GenScript Biotech Corporation
- Bio-Rad Laboratories, Inc.
- Merck KGaA
- QIAGEN N.V.
- Thermo Fisher Scientific Inc.
- Takara Bio Inc.
- Synthetic Genomics Inc.
- Lucigen Corporation
- Promega Corporation
- ARTES Biotechnology GmbH
- ProteoGenix
- Addgene Inc.
- Geneva Biotech
- Profacgen
- Peak Proteins Ltd.
